Pediatrics
Latest News
Isotretinoin users do not have higher suicide risk: meta-analysis
The analysis showed that the 1-year absolute risk from between two and eight studies of suicide attempts, suicidal ideation, completed suicides,...
Latest News
Laser epilation may reduce pilonidal disease recurrences when added to standard care
The study is “the first, to our knowledge, to compare LE as an adjunct to standard care versus standard care alone and demonstrate a decrease in...
Latest News
Tapinarof effective for AD in patients as young as 2 years
Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.
Latest News
Parent concerns a factor when treating eczema in children with darker skin types
For the parent, the pigmentation changes, rather than the inflammation, might be the governing issue and the reason that he or she brought the...
Latest News
Lebrikizumab gets European nod for treating moderate-to-severe atopic dermatitis
Lebrikizumab remains under review in the United States.
Conference Coverage
Alpha-gal syndrome: Red meat is ‘just the beginning,’ expert says
“We are seeing increasing diagnoses of AGS in places that are not, perhaps, where we first thought this allergy existed.”
Case Reports
Pediatric Primary Cutaneous Marginal Zone Lymphoma Treated With Doxycycline
Primary cutaneous marginal zone lymphoma (PCMZL) is a cutaneous B-cell lymphoma that rarely occurs in children.
Latest News
Birch bark–derived treatment reduces daily dressings in patients with epidermolysis bullosa
Despite being approved in Europe, Oleogel-S10 has not yet been approved to treat EB in the United States.
News from the FDA/CDC
FDA OKs first ustekinumab biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.
News from the FDA/CDC
FDA approves abatacept for pediatric patients with psoriatic arthritis
As many as 5% of pediatric patients with juvenile idiopathic arthritis are estimated to have juvenile PsA.
Latest News
Phase 3 trial supports topical JAK inhibitor for AD in young children
Already approved in adolescents and adults, topical ruxolitinib was found safe and effective in children.